PepGen Inc. (PEPG) - Episode 67 - Sep 25, 2025

What happens when a biotech company announces a potential miracle cure and, mere hours later, hands the market a $100 million bill? That's the complex diagnosis facing PepGen (PEPG) after a bombshell clinical trial announcement sent its stock exploding upwards on stampede-like volume, only to be followed by a massive, dilutive share offering. With a significant number of traders betting against it and a chart screaming both "breakout" and "dangerously overbought," the stock is now a major battleground. In this episode, we dissect the conflict between groundbreaking science and financial reality to determine if this explosive rally has a healthy prognosis or if it's just a flash of market fever destined to fade.